Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.89 |
| ▸ | NPC1 | O15118 | 6/20 | 0.89 |
| ▸ | RAB9A | P51151 | 6/20 | 0.89 |
| ▸ | LMNA | P02545 | 5/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.89 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.89 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.47 |
| ▸ | PTPRC | P08575 | 3/20 | 0.47 |
| ▸ | APAF1 | O14727 | 3/20 | 0.46 |
| ▸ | S100A4 | P26447 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7318179 | 0.96 | NPC1 (0.96) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| 9,10-Phenanthrenequinone SCHEMBL6059381 | 0.94 | NPC1 (0.92) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL29352712 | 0.94 | NPC1 (1.00) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| Anthraquinone SCHEMBL6310187 | 0.94 | NPC1 (1.00) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL36840 | 0.94 | NPC1 (1.00) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL27590795 | 0.92 | NPC1 (0.96) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| Water SCHEMBL28061572 | 0.92 | NPC1 (0.96) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL13437909 | 0.92 | SMN1; SMN2 (0.80) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| Formaldehyde SCHEMBL28131826 | 0.90 | NPC1 (0.92) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL19396241 | 0.87 | SMN1; SMN2 (0.88) | MAPTNPC1RAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115528215-A | Secondary battery positive electrode material pre-ionization reagent and preparation method and application thereof | 深圳珈钠能源科技有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-115528215-A | Secondary battery positive electrode material pre-ionization reagent and preparation method and application thereof | 深圳珈钠能源科技有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-9637565-B2 | Photoinitiating system for anionic polymerization | UVIC INDUSTRY PARTNERSHIPS INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| EP-0886182-A1 | Positive photoresist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | MAPT 3475/4885NPC1 2764/4885RAB9A 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.